InfuSystem Holdings, Inc. Reports Second Quarter 2017 Financial Results
MADISON HEIGHTS, Mich., Aug. 9, 2017 /PRNewswire/ -- InfuSystem Holdings, Inc. (NYSE MKT: INFU) ("InfuSystem" or the "Company"), a leading national provider of infusion pumps and related services for the healthcare industry in the United States, today reported financial results for the quarter ended June 30, 2017.
Second Quarter 2017 Overview:
-- Net revenues totaled $16.9 million, a decrease of 6.5%, versus the
second quarter of 2016 of $18.1 million;
-- Rental revenues decreased $1.5 million, or 9.1%, in the second
quarter of 2017 compared to the second quarter of 2016;
-- Product sales increased 15.5% to $2.2 million in the second quarter
of 2017 compared to the second quarter of 2016;
-- Gross profit was $10.3 million, a decrease of $0.8 million, or 7.2%,
compared to the second quarter of 2016;
-- Gross margin was 61.0% compared to 61.5% for the second quarter of 2016;
-- General and administrative ("G&A") expenses increased less than 1% to
$6.4 million compared to the second quarter of 2016; this amount
included approximately $1.0 million related to severance costs, legal
expenses and capital lease early termination expenses;
-- Net Debt (Total Debt net of Cash) decreased $2.9 million to $32.1
million in the second quarter of 2017 compared to the first quarter of
2017;
-- Provision for doubtful accounts ("Bad Debt") increased $0.3 million, to
$1.3 million, compared to the second quarter of 2016, including $0.2
million in additional reserves related to delayed collections due to
changed billing practices following SE1609 that was announced last year
by the Centers for Medicare and Medicaid Services ("CMS");
-- Net loss of $1.1 million, or $0.05 loss per diluted share, compared to
second quarter 2016 net income of $0.2 million, or $0.01 income per
diluted share;
-- Net collected revenues (a non-GAAP financial measure) decreased 8.4%, to
$15.6 million, compared to the second quarter of 2016;
-- Adjusted EBITDA margin (a non-GAAP financial measure) decreased slightly
in the second quarter of 2017 to 18.1% compared to 18.8% in the second
quarter of 2016 but increased 9.9% compared to the first quarter of
2017;
-- Adjusted EBITDA (a non-GAAP financial measure) decreased 10.0% to $3.1
million compared to the second quarter of 2016 but increased $1.6
million, or 113%, compared to the first quarter of 2017.
Management Discussion
Gregg Lehman, executive chairman of the board, said, "After a thorough review, we concluded that InfuSystem is not lacking for new business opportunities. Both our third-party payor salesforce and our direct payor salesforce are very active and we expect that will continue going forward. Where the Company needs to make significant progress is in collecting the revenue that is due from the growing number of procedures that take place utilizing our equipment. If we don't collect the revenue that is due to us on a timely basis, it doesn't matter how many pumps are deployed or how many procedures are being performed. Improving our collections practices is important in returning the Company to improved liquidity and profitability and it also effects how InfuSystem recognizes its collected net revenue. Improved collections results in the Company recognizing increased net revenues."
"Accordingly, during the second quarter of 2017, InfuSystem redirected its strategic emphasis away from expanding our pump fleet and toward increasing efficiencies, particularly in the billing and collections area. With a combination of in-house and outsourced personnel, we are totally dedicated to collecting the revenue that is legitimately due InfuSystem from both third-party payors and direct payors. The emphasis on effective collections will improve quarterly revenue, reduce write-offs for bad debt and generate cash that will allow the Company to reduce its bank indebtedness."
Dr. Lehman continued, "On a sequential basis, cash collections for the second quarter of 2017 were up $0.9 million, or 14%, for our commercial payors compared to the first quarter of 2017 and our adjusted EBITDA (a non-GAAP performance metric) increased $1.6 million, or 113%, versus the first quarter of 2017. In addition, as part of our strategic initiative to manage our pump fleet, reduce expenses and better management of our working capital, we were able to reduce our net debt by $2.9 million during the second quarter of 2017. I am pleased our adjusted EBITDA run rate was approximately $3.1 million in the second quarter and we expect that to continue to be the case for the second half of the year."
"I am particularly pleased with the performance of the Office of the President, the leadership group I formed in May that includes certain directors and key senior management to oversee operations. We have worked well together in identifying the issues, crafting solutions and adopting "best practices" successfully executing our strategic initiatives. We have also successfully amended the terms of the credit facility that provides the Company with favorable terms and financial flexibility. It is important to note that we have embarked on a process to recalibrate this business that will take some time, however, we firmly believe that we are heading in the right direction," concluded Dr. Lehman.
Second Quarter Results
Net revenues for the quarter ended June 30, 2017 were $16.9 million, a decrease of $1.2 million, or 6.5%, compared to $18.1 million for the quarter ended June 30, 2016. During the period, net revenues from rentals decreased $1.5 million, or 9.1%, compared to the same prior year period. The decrease in net revenues from rentals can be largely attributed to (i) changed practices and reduced billing rates due to the CMS Medical Learning Network Matters article number SE1609 ("SE1609") regulatory change effecting net revenue by approximately $1.3 million and (ii) pricing and collection impacts of $1.1 million. These decreases were offset by an overall increase in rental volume of $0.9 million with new and existing sites of therapy. Net revenues from product sales were $2.2 million, an increase of $0.3 million compared to the same prior year period.
Net collected rental revenues, or net revenues from rentals less provision for doubtful accounts (a non-GAAP financial measure), was $13.4 million in the second quarter of 2017, a decrease of 11.4%, compared to $15.2 million in the second quarter of 2016.
Bad Debt for the quarter ended June 30, 2017 was $1.3 million, an increase of $0.3 million, or 24.3%, compared to the quarter ended June 30, 2016. Bad Debt was 7.8% of revenues for the second quarter of 2017, compared to 5.9% for the same prior year period. This change is largely due to increased reserves for amounts uncollected following our implementation, on July 1, 2016, of revised billing practices for Medicare accounts as required by SE1609. We now directly bill providors and not third-party payors for SE1609 related services. Because this is a dramatic change from prior practices, we have experienced a delay in providors acknowledging and paying under the new model. We continue to see improvements in collections from SE1609 providors since the initial implementation in July 2016, but nonetheless, we have adopted the practice of reserving for all SE1609 accounts receivable aged greater than 90 days. We believe the strategic shift to focusing additional resources on collection efforts will deliver a positive impact with respect to these SE1609 accounts receivables.
Gross profit for the second quarter of 2017 was $10.3 million, a decrease of 7.2%, compared to $11.1 million for the same prior year period. As a percentage of net revenues, gross profit equaled 61.0% of total net revenues in the second quarter of 2017 compared to 61.5% in the prior year's comparable quarter. The decrease in gross profit for the second quarter of 2017 was largely attributed to the decrease in net revenues of $1.2 million for the period, which was offset by a decrease of $0.2 million in product and supply costs, $0.1 million in the costs of pumps sold and $0.1 million in pump depreciation and disposals.
For the second quarter of 2017, G&A expenses were $6.4 million, an increase of less than $0.1 million, or 0.5%, compared to the same prior year period. Included in G&A during the quarter were some expenses not typical of our ongoing operations, including $0.5 million of management reorganization expenses related to severance costs for our previous CEO, $0.2 million of legal expenses related to defending a shareholder lawsuit and $0.3 million of early termination fees related to capital leases repaid in response to the Third Amendment to our Credit Agreement with Chase Bank finalized during the second quarter of 2017.
Other expenses for the second quarter of 2017 were $0.4 million compared to $0.3 million for the same period in 2016. Selling and marketing expenses for the 2017 second quarter were $2.3 million, a decrease of less than $0.1 million, or 1.2%, compared to the second quarter of 2016.
Net loss in the second quarter of 2017 was $1.1 million, or $0.05 loss per diluted share, compared to net income of $0.2 million, or $0.01 income per diluted share, in the same prior year period. Adjusted net loss, excluding non-recurring items (a non-GAAP financial measure), was $0.4 million, or $0.02 loss per diluted share, compared to adjusted net income of $0.4 million, or $0.02 income per diluted share, for the same prior year period.
For the second quarter of 2017, adjusted EBITDA (a non-GAAP financial measure) was $3.1 million, a decrease of 10.0%, compared to $3.4 million for the same period in 2016. The Company utilizes adjusted net (loss) income and adjusted EBITDA as a means to measure its operating performance. A reconciliation from GAAP operating measures to adjusted net (loss) income and adjusted EBITDA, both non-GAAP measures, can be found in the appendix attached to this press release. Adjustments during the second quarter of 2017 included, among other adjustments, expenses for severance, costs associated with shareholder litigation and early termination fees from paying down capital leases.
Financial Condition
Net cash provided by operations for the six months ended June 30, 2017, was $1.2 million compared to $1.9 million for the six months ended June 30, 2016. This decrease is due to higher amounts of non-cash expenses (such as deferred income taxes) and other liabilities in the current period, which were offset by decreases in accounts payable and other current liabilities. The Company reduced its investment in medical equipment during the quarter in anticipation of increasing utilization on available assets.
Net cash provided by investing activities was $0.7 million for the six months ended June 30, 2017 compared to $5.4 million used in the six months ended June 30, 2016. This $6.1 million increase was due to reduced pump purchases and increased pump sales during the second quarter of 2017.
Net cash used in financing activities for the six months ended June 30, 2017, was $5.3 million compared to net cash provided by financing activities of $3.5 million for the same prior year period. This change is primarily attributable to the cash proceeds received from our decision to borrow from the revolving credit line under our Credit Facility during the first half of 2016, as well as, our decision to pay down a majority of our capital lease obligations during the first half of 2017.
As of June 30, 2017, we maintained cash and cash equivalents of $0.1 million and $8.6 million of net availability under our revolving credit facility compared to $3.4 million of cash and cash equivalents and $9.9 million of net availability, respectively, at December 31, 2016.
Conference Call
The Company will conduct a conference call for investors on Wednesday, August 9, 2017 at 4:30 p.m. Eastern Time to discuss second quarter performance and results. Gregg Lehman, executive chairman of the board, Jan Skonieczny, chief operating officer, Chris Downs, interim chief financial officer, Rich DiIorio, general manager of oncology and Trent Smith, chief accounting officer will discuss the Company's financial performance and answer questions from the financial community. To participate in this call, please dial in toll-free (800) 446-2782 and use the confirmation number 45427320. This press release will be available on most financial websites. Additionally, a web replay will be available on the Company's website for 30 days.
Non-GAAP Measures
This press release contains information prepared in conformity with GAAP as well as non-GAAP financial information. The Company believes that the non-GAAP financial measures presented in this press release provide useful information to the Company's management, investors, and other interested parties about the Company's operating performance because they allow them to understand and compare the Company's operating results during the current periods to the prior year periods in a more consistent manner. It is management's intent to provide non-GAAP financial information in order to enhance readers' understanding of its consolidated financial information as prepared in accordance with GAAP. This non-GAAP information should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. Each non-GAAP financial measure and the corresponding GAAP financial measures are presented so as to not imply that more emphasis should be placed on the non-GAAP measure. The non-GAAP financial information presented may be determined or calculated differently by other companies. Additional information about non-GAAP financial measures and a reconciliation of those measures to the most directly comparable GAAP measures are included later in this release.
About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services to hospitals, oncology practices and other alternate site healthcare providors. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Texas, Georgia and Ontario, Canada. The Company's stock is traded on the NYSE MKT under the symbol INFU.
Forward-Looking Statements
The financial results in this press release reflect preliminary results, which are not final until the Company's Form 10-Q for the second quarter of 2017 is filed. In addition, certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "strategy," "future," "likely," variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements include statements relating to future actions, business plans, objectives and prospects, future operating or financial performance, including the preliminary financial results contained in this press release. In connection with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors that could cause actual results to differ, perhaps materially, from those indicated by these forward-looking statements. Those factors, risks and uncertainties include, but are not limited to, the potential changes in overall healthcare reimbursement, including CMS competitive bidding, sequestration, concentration of customers, increased focus on early detection of cancer, competitive treatments, dependency on Medicare Supplier Number, availability of chemotherapy drugs, global financial conditions, changes and enforcement of state and federal laws, natural forces, competition, dependency on suppliers, risks in acquisitions & joint ventures, U.S. Healthcare Reform, relationships with healthcare professionals and organizations, technological changes related to infusion therapy, dependency on websites and intellectual property, the ability of the Company to successfully integrate acquired businesses, dependency on key personnel, dependency on banking relations and covenants, and other risks associated with our common stock, as well as any litigation to which the Company may be involved in from time to time; and other risk factors as discussed in the Company's annual report on Form 10-K for the year ended December 31, 2016 and in other filings made by the Company from time to time with the Securities and Exchange Commission, including our quarterly reports on Form 10-Q. Our annual report on Form 10-K is available on the SEC's EDGAR website at www.sec.gov, and a copy may also be obtained by contacting the Company. All forward-looking statements made in this press release speak only as of the date hereof. We do not intend, and do not undertake any obligation, to update any forward-looking statements to reflect future events or circumstances after the date of such statements, except as required by law.
Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com.
FINANCIAL TABLES FOLLOW
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
As of
-----
June 30, December 31,
(in thousands, except share data) 2017 2016
-------------------------------- ---- ----
(Unaudited)
ASSETS
Current Assets:
Cash and cash equivalents $76 $3,398
Accounts receivable, less allowance for
doubtful accounts of $6,189 and $4,989
at June 30, 2017 and December 31, 2016,
respectively 11,547 11,581
Inventory 1,962 2,166
Other current assets 1,314 949
Deferred income taxes - 2,675
--- -----
Total Current Assets 14,899 20,769
Medical equipment held for sale or rental 1,289 1,642
Medical equipment in rental service, net
of accumulated depreciation 25,715 28,036
Property & equipment, net of accumulated
depreciation 1,815 1,997
Intangible assets, net 28,293 31,239
Deferred income taxes 16,638 12,436
Other assets 61 225
--- ---
Total Assets $88,710 $96,344
======= =======
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable $5,247 $5,315
Capital leases 593 2,938
Current portion of long-term debt 2,660 5,314
Other current liabilities 2,494 2,872
----- -----
Total Current Liabilities 10,994 16,439
Long-term debt, net of current portion 28,719 26,577
Capital leases 238 2,573
Other long-term liabilities 61 66
--- ---
Total Long-Term Liabilities 29,018 29,216
Total Liabilities $40,012 $45,655
------- -------
Stockholders' Equity:
Preferred stock, $.0001 par value:
authorized 1,000,000 shares; none issued - -
2 2
Common stock, $.0001 par value: authorized 200,000,000
shares; issued and outstanding 22,953,365 and
22,755,705,respectively, as of June 30, 2017 and
22,867,335 and 22,669,675, respectively, as of
December 31, 2016
Additional paid-in capital 92,206 91,829
-
Retained deficit (43,510) (41,142)
------- -------
Total Stockholders' Equity 48,698 50,689
------ ------
Total Liabilities and Stockholders'
Equity $88,710 $96,344
======= =======
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Three Months Ended Six Months Ended
(in thousands, except share and per share data) June 30 June 30
---------------------------------------------- ------- -------
2017 2016 2017 2016
---- ---- ---- ----
Net revenues:
Rentals $14,769 $16,242 $29,906 $32,730
Product Sales 2,173 1,881 4,690 3,687
----- ----- ----- -----
Net revenues 16,942 18,123 34,596 36,417
Cost of revenues:
Cost of revenues - Product, service and supply costs 4,624 4,789 9,160 8,295
Cost of revenues - Pump depreciation and disposals 1,977 2,191 4,446 4,422
----- ----- ----- -----
Gross profit 10,341 11,143 20,990 23,700
------ ------ ------ ------
Selling, general and administrative expenses:
Provision for doubtful accounts 1,326 1,067 3,182 2,814
Amortization of intangibles 1,387 922 2,798 1,834
Selling and marketing 2,295 2,324 5,181 5,139
General and administrative 6,425 6,392 12,890 13,061
----- ----- ------ ------
Total selling, general and administrative 11,433 10,705 24,051 22,848
------ ------ ------ ------
Operating (loss) income (1,092) 438 (3,061) 852
Other income (expense):
Interest expense (333) (327) (661) (632)
Other (expense) income (66) 7 (103) 27
--- --- ---- ---
Total other expense (399) (320) (764) (605)
(Loss) income before income taxes (1,491) 118 (3,825) 247
Income tax benefit (expense) 385 35 1,241 (53)
--- --- ----- ---
Net (loss) income $(1,106) $153 $(2,584) $194
======= ==== ======= ====
Net (loss) income per share:
Basic $(0.05) $0.01 (0.11) 0.01
Diluted $(0.05) $0.01 (0.11) 0.01
Weighted average shares outstanding:
Basic 22,740,050 22,620,386 22,710,470 22,584,462
Diluted 22,740,050 23,109,870 22,710,470 23,069,900
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Six Months Ended
June 30
-------
(in thousands) 2017 2016
---- ----
NET CASH PROVIDED BY OPERATING
ACTIVITIES $1,231 $1,869
------ ------
INVESTING ACTIVITIES
Purchase of medical equipment and
property (1,893) (7,187)
Proceeds from sale of medical
equipment and property 2,623 1,827
----- -----
NET CASH PROVIDED BY (USED IN)
INVESTING ACTIVITIES 730 (5,360)
--- ------
FINANCING ACTIVITIES
Principal payments on revolving
credit facility, term loans and
capital lease obligations (24,419) (29,190)
Cash proceeds from revolving credit
facility 19,105 32,575
Debt issuance costs (28) -
Common stock repurchased to satisfy
statutory withholding on employee
stock based compensation plans (28) (33)
Cash proceeds from stock plans 87 126
--- ---
NET CASH (USED IN) PROVIDED BY
FINANCING ACTIVITIES (5,283) 3,478
------ -----
Net change in cash and cash
equivalents (3,322) (13)
Cash and cash equivalents, beginning
of period 3,398 818
----- ---
Cash and cash equivalents, end of
period $76 $805
=== ====
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION
(UNAUDITED)
NET (LOSS) INCOME TO ADJUSTED NET (LOSS)
INCOME:
Three Months Ended Six Months Ended
June 30, June 30,
-------- --------
(in thousands) 2017 2016 2017 2016
------------- ---- ---- ---- ----
GAAP net (loss) income $(1,106) $153 $(2,584) $194
Adjustments:
Restatement costs - - 28 -
Early termination fees for capital leases 302 - 302 -
Strategic alternatives and other costs - 95 - 195
Shareholder legal costs 176 - 200 -
Management reorganization 485 75 619 75
Income tax (benefit) expense (385) (35) (1,241) 53
---- --- ------ ---
(Loss) Income before income taxes -
adjusted $(528) $288 $(2,676) $517
Income tax benefit (expense) relating to
adjustments (1) 136 86 867 (111)
--- --- --- ----
Non-GAAP adjusted net (loss) income $(392) $374 $(1,809) $406
===== ==== ======= ====
RECONCILIATION OF GAAP NET (LOSS) INCOME
PER DILUTED COMMON SHARE TO NON-GAAP
ADJUSTED NET (LOSS) INCOME PER DILUTED
COMMON SHARE
GAAP net (loss) income per diluted common
share: $(0.05) $0.01 $(0.11) $0.01
Adjustments:
Early termination fees for capital leases 0.01 - 0.01 -
Strategic alternatives and other costs - 0.00 - 0.01
Shareholder legal costs 0.01 - 0.01 -
Management reorganization 0.02 0.00 0.03 -
Income tax (benefit) expense (0.02) (0.00) (0.05) -
----- ----- ----- ---
(Loss) Income before income taxes -
adjusted $(0.03) $0.01 $(0.12) $0.02
Income tax benefit (expense) relating to
adjustments (1) 0.01 0.01 0.04 -
---- ---- ---- ---
Non-GAAP net (loss) income per diluted
common share: $(0.02) $0.02 $(0.08) $0.02
Weighted average shares outstanding:
Basic 22,740,050 22,620,386 22,710,470 22,584,462
Diluted 22,740,050 23,109,870 22,710,470 23,069,900
(1) Rate used to calculate income
tax benefit (expense) for the
periods was the Company's
effective tax rate before
adjustments.
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION (CONTINUED)
(UNAUDITED)
NET (LOSS) INCOME TO ADJUSTED
EBITDA:
Three Months Ended Six Months Ended
June 30, June 30,
-------- --------
(in thousands) 2017 2016 2017 2016
------------- ---- ---- ---- ----
GAAP net (loss) income $(1,106) $153 $(2,584) $194
Adjustments:
Interest expense 333 327 661 632
Income tax (benefit) expense (385) (35) (1,241) 53
Depreciation 1,693 1,730 3,400 3,373
Amortization 1,387 922 2,798 1,834
----- --- ----- -----
GAAP EBITDA $1,922 $3,097 $3,034 $6,086
Stock compensation 178 137 318 350
Restatement costs - - 28 -
Early termination fees for
capital leases 302 - 302 -
Strategic alternatives and
other costs - 95 - 195
Shareholder legal costs 176 - 200 -
Management reorganization 485 75 619 75
Non-GAAP Adjusted EBITDA $3,063 $3,404 $4,501 $6,706
====== ====== ====== ======
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION (CONTINUED)
(UNAUDITED)
NET COLLECTED REVENUES
Three Months Ended Six Months Ended
June 30, June 30,
-------- --------
(in thousands) 2017 2016 2017 2016
------------- ---- ---- ---- ----
Net Revenues:
Rentals $14,769 $16,242 $29,906 $32,730
Product sales 2,173 1,881 4,690 3,687
----- ----- ----- -----
Total Net Revenues 16,942 18,123 34,596 36,417
Adjustments:
Less: Provision for Doubtful
Accounts (1,326) (1,067) (3,182) (2,814)
------ ------ ------ ------
Non-GAAP total - net
collected revenues -
adjusted $15,616 $17,056 $31,414 $33,603
======= ======= ======= =======
NET COLLECTED RENTAL REVENUES
Three Months Ended Six Months Ended
June 30, June 30,
-------- --------
(in thousands) 2017 2016 2017 2016
------------- ---- ---- ---- ----
Net Revenues:
Rentals $14,769 $16,242 $29,906 $32,730
Adjustments:
Less: Provision for Doubtful
Accounts (1,326) (1,067) (3,182) (2,814)
------ ------ ------ ------
Non-GAAP total - net
collected rental revenues -
adjusted $13,443 $15,175 $26,724 $29,916
======= ======= ======= =======
CONTACT: Joe Dorame, Joe Diaz &
Robert Blum
Lytham Partners, LLC
602-889-9700
View original content with multimedia:http://www.prnewswire.com/news-releases/infusystem-holdings-inc-reports-second-quarter-2017-financial-results-300502189.html
SOURCE InfuSystem Holdings, Inc.
